Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era

Journal of Oral Pathology and Medicine

Volumn 38, Issue 8, 2009, Pages 613-622

  Pinheiro, Raquel Dos Santos ^a   França, Talita Tenório ^b   Ribeiro, Camila Maria Beder ^c   Leão, Jair Carneiro ^b   Ribeiro de Souza, Ivete Pomarico ^a   Castro, Gloria Fernanda ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

AIDS; HIV infection; Oral mucosa

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; RETINOL; ZIDOVUDINE;

CANCER RISK; CHILD; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; MORBIDITY; MORTALITY; MOUTH CARCINOMA; MOUTH LESION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DENTAL CARE FOR CHILDREN; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARIES; HEALTH STATUS; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MOUTH DISEASES; OPPORTUNISTIC INFECTIONS; ORAL HEALTH; SALIVARY GLAND DISEASES; VIRUS DISEASES;

EID: 70350328702     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00789.x     Document Type: Review

References (119)

1. Merchant RH, Oswal JS, Bhagwat RV, Karkare J. Clinical profile of HIV infection. Indian Pediatr 2001; 38: 239-246.
2. UNAIDS World Health Organization, 2007. Available at: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf (accessed on 11 February, 2008).
3. SAÚDE-RIO. SECRETARIA MUNICIPAL DE SAÚDE DO RIO DE JANEIRO; Programa DST/ AIDS. Vigilância Epidemiológica. Série História de casos de AIDS em crianças. Rio de Janeiro; 1984 a 2005; Available at: http://www.saude.rio.rj.gov.br/media/dstaids-seriehistorica- criancas-2005.pdf. (accessed on 5 May, 2008).
4. Dias EP, Israel MS, Silva Junior A, Maciel VA, Gagliardi JP, Oliveira RH. Prevalence of oral hairy leukoplakia in 120 pediatric patients infected with HIV-1. Braz Oral Res 2006; 20: 103-107.
5. Ramos-Gomez F. Dental considerations for the paediatric AIDS / HIV patient. Oral Dis 2002; 8(Suppl. 2): 49-54.
6. Naidoo S, Chikte U. Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. Oral Dis 2004; 10: 13-18.
7. Chigurupati R, Raghavan SS, Studen-Pavlovich DA. Pediatric HIV infection and its oral manifestations: a review. Pediatr Dent 1996; 18: 106-113.
8. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A. Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. J Clin Pediatr Dent 1999; 23: 85-96.
9. Quinn TC, Mann JM, Curran JW, Piot P. AIDS in Africa: an epidemiologic paradigm. Science 1986; 234: 955-963.
10. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 354-358.
11. Thiry L, Sprecher-Goldberger S, Jonckheer T, et al. Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet 1985; 2: 891-892.
12. Salvatori F, De Martino M, Galli L, Vierucci A, Chieco-Bianchi L, De Rossi A. Horizontal transmission of human immunodeficiency virus type 1 from father to child. AIDS Res Hum Retroviruses 1998; 14: 1679-1685. (Pubitemid 28563859)
13. French MA, Herring BL, Kaldor JM, et al. Intrafamilial transmission of HIV-1 infection from individuals with unrecognized HIV-1 infection. AIDS 2003; 17: 1977-1981.
14. Lapointe N, Michaud J, Pekovic D, Chausseau JP, Dupuy JM. Transplacental transmission of HTLV-III virus. N Engl J Med 1985; 312: 1325-1326.
15. Lewis DE, Giorgi JV. Immunology of HIV infection. Int Rev Immunol 1990; 7: 1-13.
16. Scarlatti G. Paediatric HIV infection. Lancet 1996; 348: 863-868.
17. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
18. Castetbon K, Leroy V, Spira R, Dabis F. [Preventing the transmission of HIV-1 from mother to child in Africa in the year 2000]. Sante 2000; 10: 103-113. (Pubitemid 30646729)
19. Coutsoudis A, Bobat RA, Coovadia HM, Kuhn L, Tsai WY, Stein ZA. The effects of vitamin A supplementation on the morbidity of children born to HIVinfected women. Am J Public Health 1995; 85(8 Pt 1): 1076-1081.
20. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860
21. Miziara ID, Weber R. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med 2008; 37: 99-106.
22. Shelburne SA III, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-227.
23. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 447-454.
24. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30: 882-892.
25. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
26. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38: 1159-1166.
27. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1815-1822.
28. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIVinfected patients with highly active antiretroviral therapy. HIV Med 2000; 1: 107-115.
29. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids. 2005; 19: 399-406.
30. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006; 25: 53-58.
31. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS 2003; 17: 2129-2131.
32. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV / tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37: 1574-1576.
33. Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. J Oral Pathol Med 1993; 22: 289-291.
34. Sullivan D, Bennett D, Henman M, et al. Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J Clin Microbiol 1993; 31: 2124-2133.
35. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis 2002; 8(Suppl. 2): 98-109.
36. Frezzini C, Leao JC, Porter S. Current trends of HIV disease of the mouth. J Oral Pathol Med 2005; 34: 513-531.
37. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AA, Kelley JI, Meiller TF. Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIVinfected individuals. J Clin Microbiol 2000; 38: 2423-2426.
38. Aguirre JM. Lesiones orales asociadas a la infecció n VIH. Rev vasca de odontoestomatol 1992; 2: 55-62.
39. Leggott PJ. Oral manifestations of HIV infection in children. Oral Surg Oral Med Oral Pathol 1992; 73: 187-192.
40. Pol RR, Shepur TA, Ratageri VH. Clinico-laboratory profile of pediatric HIV in Karnataka. Indian J Pediatr 2007; 74: 1071-1075.
41. Ketchem L, Berkowitz RJ, McIlveen L, Forrester D, Rakusan T. Oral findings in HIV-seropositive children. Pediatr Dent 1990; 12: 143-146.
42. Katz MH, Mastrucci MT, Leggott PJ, Westenhouse J, Greenspan JS, Scott GB. Prognostic significance of oral lesions in children with perinatally acquired human immunodeficiency virus infection. Am J Dis Child 1993; 147: 45-48.
43. Moniaci D, Cavallari M, Greco D, et al. Oral lesions in children born to HIV-1 positive women. J Oral Pathol Med 1993; 22: 8-11.
44. Valdez IH, Pizzo PA, Atkinson JC. Oral health of pediatric AIDS patients: a hospital-based study. ASDC J Dent Child 1994; 61: 114-118.
45. Del Toro A, Berkowitz R, Meyerowitz C, Frenkel LM. Oral findings in asymptomatic (P-1) and symptomatic (P-2) HIV infected children. Pediatr Dent 1996; 18: 114-116.
46. Howell RB, Jandinski JJ, Palumbo P, Shey Z, Houpt MI. Oral soft tissue manifestations and CD4 lymphocyte counts in HIV-infected children. Pediatr Dent 1996; 18: 117-120.
47. Cerqueira DF, Portela MB, Pomarico L, Soares RM, de Souza IP, Castro GF. Examining dentinal carious lesions as a predisposing factor for the oral prevalence of Candida spp in HIV-infected children. J Dent Child (Chic) 2007; 74: 98-103.
48. Ramos-Gomez FJ, Hilton JF, Canchola AJ, Greenspan D, Greenspan JS, Maldonado YA. Risk factors for HIVrelated orofacial soft-tissue manifestations in children. Pediatr Dent 1996; 18: 121-126.
49. Pongsiriwet S, Iamaroon A, Kanjanavanit S, Pattanaporn K, Krisanaprakornkit S. Oral lesions and dental caries status in perinatally HIV-infected children in Northern Thailand. Int J Paediatr Dent 2003; 13: 180-185.
50. Santos LC, Castro GF, de Souza IP, Oliveira RH. Oral manifestations related to immunosuppression degree in HIV-positive children. Braz Dent J 2001; 12: 135-138.
51. Magalhaes MG, Bueno DF, Serra E, Goncalves R. Oral manifestations of HIV positive children. J Clin Pediatr Dent 2001; 25: 103-106.
52. Samaranayake LP, Fidel PL, Naglik JR, et al. Fungal infections associated with HIV infection. Oral Dis 2002; 8(Suppl. 2): 151-160.
53. MacPhail LA, Hilton JF, Heinic GS, Greenspan D. Direct immunofluorescence vs. culture for detecting HSV in oral ulcers: a comparison. J Am Dent Assoc 1995; 126: 74-78.
54. Regezi JA, Eversole LR, Barker BF, Rick GM, Silverman S Jr. Herpes simplex and cytomegalovirus coinfected oral ulcers in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81: 55-62.
55. Syrjanen S, Leimola-Virtanen R, Schmidt-Westhausen A, Reichart PA. Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. J Oral Pathol Med 1999; 28: 204-209.
56. Grando LJ, Machado DC, Spitzer S, et al. Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+ T lymphocyte count and detection of EBV, CMV and HSV. Braz Oral Res 2005; 19: 228-234.
57. Magalhães M, Bueno D, Serra E, Gonçalves R. Oral manifestations of HIV positive children. Int Dent J 2004; 54: 131-137.
58. Delgado AJE, Bolaños EV, Cobo EGM. Manifestaciones orales de la infección por VIH en la infancia: artículo de revisión. Med Oral Patol Oral Cir Bucal 2004; 9: 410-420.
59. Santos RA, Hatfield CC, Cole NL, et al. Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virol 2000; 275: 306-317.
60. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008; 121: e150-6.
61. Hamza OJ, Matee MI, Simon EN, et al. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006; 6: 12.
62. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 2004; 113: 742-746.
63. Fonseca R, Cardoso AS, Pomarico I. Frequency of oral manifestations in children infected with human immunodeficiency virus. Quintessence Int 2000; 31: 419-422.
64. Costa LR, Villena RS, Sucasas PS, Birman EG. Oral findings in pediatric AIDS: a case control study in Brazilian children. ASDC J Dent Child 1998; 65: 186-190.
65. Ferguson FS, Archard H, Nuovo GJ, Nachman S. Hairy leukoplakia in a child with AIDS - a rare symptom: case report. Pediatr Dent 1993; 15: 280-281.
66. Gaitan-Cepeda L, Cashat-Cruz M, Morales-Aguirre JJ, et al. Prevalence of oral lesions in Mexican children with perinatally acquired HIV: association with immunologic status, viral load, and gender. AIDS Patient Care STDS 2002; 16: 151-156.
67. Greenspan JS, Mastrucci MT, Leggott PJ, et al. Hairy leukoplakia in a child. AIDS 1988; 2: 143.
68. Itin PH, Bircher AJ, Litzisdorf Y, Rudin C. Oral hairy leukoplakia in a child: confirmation of the clinical diagnosis by ultrastructural examination of exfoliative cytologic specimens. Dermatology 1994; 189: 167-169.
69. Portela MB, Souza IP, Costa EM, Hagler AN, Soares RM, Santos AL. Differential recovery of Candida species from subgingival sites in human immunodeficiency virus-positive and healthy children from Rio de Janeiro, Brazil. J Clin Microbiol 2004; 42: 5925-5927.
70. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDSassociated Kaposi's sarcoma. J Am Acad Dermatol 1990; 22(6 Pt 2): 1237-1250.
71. Andreoni M, El-Sawaf G, Rezza G, et al. High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. J Natl Cancer Inst 1999; 91: 465-469.
72. Serraino D, Locatelli M, Songini M, et al. Human herpes virus-8 infection among pregnant women and their children: results from the Sardinia-IDDM Study 2. Int J Cancer 2001; 91: 740-741.
73. Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000; 356: 1062-1065.
74. Olsen SJ, Chang Y, Moore PS, Biggar RJ, Melbye M. Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. AIDS 1998; 12: 1921-1925.
75. He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and motherchild pairs with KS. J Infect Dis 1998; 178: 1787-1790.
76. Blauvelt A, Sei S, Cook PM, Schulz TF, Jeang KT. Human herpesvirus 8 infection occurs following adolescence in the United States. J Infect Dis 1997; 176: 771-774.
77. Cook RD, Hodgson TA, Waugh AC, et al. Mixed patterns of transmission of human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) in Malawian families. J Gen Virol 2002; 83(Pt 7): 1613-1619.
78. Brayfield BP, Phiri S, Kankasa C, et al. Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis 2003; 187: 559-568.
79. Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa. J Gen Virol 1997; 78(Pt 4): 847-855.
80. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirusassociated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34: 641-648.
81. Nittayananta W, Chanowanna N, Sripatanakul S, Winn T. Risk factors associated with oral lesions in HIVinfected heterosexual people and intravenous drug users in Thailand. J Oral Pathol Med 2001; 30: 224-230.
82. Dave SP, Pernas FG, Roy S. The benign lymphoepithelial cyst and a classification system for lymphocytic parotid gland enlargement in the pediatric HIV population. Laryngoscope 2007; 117: 106-113.
83. Navazesh M, Mulligan R, Barron Y, et al. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 693-698.
84. Valentine C, Deenmamode J, Sherwood R. Xerostomia associated with didanosine. Lancet 1992; 340: 1542-1543
85. Reznik D. Oral Manifestations of HIV Disease. Top HIV Med 2005; 13: 143-148.
86. Chhieng DC, Argosino R, McKenna BJ, Cangiarella JF, Cohen JM. Utility of fine-needle aspiration in the diagnosis of salivary gland lesions in patients infected with human immunodeficiency virus. Diagn ytopathol 1999; 21: 260-264.
87. Robinson PG, Boulter A, Birnbaum W, Johnson NW. A controlled study of relative periodontal attachment loss in people with HIV infection. J Clin Periodontol 2000; 27: 273-276.
88. 1999 International International Workshop for a Classification of Periodontal Diseases and Conditions. Papers. Oak Brook, Illinois, October 30-November 2, 1999. Ann Periodontol 1999; 4: 1 112.
89. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis 2000; 6: 152-157.
90. Hicks MJ, Flaitz CM, Carter AB, et al. Dental caries in HIV-infected children: a longitudinal study. Pediatr Dent 2000; 22: 359-364.
91. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59-66.
92. Soares LF, Castro GFA, de Souza IP, Pinheiro M. Pediatric HIV-related oral manifestations: a five-year retrospective study. Braz Oral Res. 2004; 18: 6-11.
93. Ribeiro AA, Portela M, Souza IP. Relação entre biofilme, atividade de carie e gengivite em crianças HIV+. Pesq Odontol Bras 2002; 16: 144-150.
94. Souza IPR, Castro GF. Abordagem odontológica da criança infectada pelo HIV. São Paulo: Livraria Santos Editora, 2008.
95. Lamster IB, Grbic JT, Mitchell-Lewis DA, Begg MD, Mitchell A. New concepts regarding the pathogenesis of periodontal disease in HIV infection. Ann Periodontol 1998; 3: 62-75.
96. Ramos-Gomez FJ, Petru A, Hilton JF, Canchola AJ, Wara D, Greenspan JS. Oral manifestations and dental status in paediatric HIV infection. Int J Paediatr Dent 2000; 10: 3-11.
97. Goetghebuer T, Haelterman E, Marvillet I, et al. Vertical transmission of HIV in Belgium: a 1986-2002 retrospective analysis. Eur J Pediatr 2009; 168: 79-85.
98. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L. (B3) Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res 2006; 19: 146-151.
99. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero JA-, Saavedra G, Gonzalez-Ramírez I. P-d-LS. The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: a 12-year study in a referral center in Mexico. Medicine (Balt) 2003; 82: 39-50.
100. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
101. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/ AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000; 14: 627-635.
102. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIVinfected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 623-628.
103. Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective casecontrol study. J Acquir Immune Defic Syndr 1999; 21: 20-25.
104. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. Oral manifestations of an HIV positive cohort in the era of highly active antiretroviral therapy (HAART) in South London. J Oral Pathol Med 2002; 31: 169-174.
105. Munro CA, Hube B. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol 2002; 10: 173-177.
106. Ranganathan K, Hemalatha R. Oral lesions in HIV infection in developing countries: an overview. Adv Dent Res 2006; 19: 63-68.
107. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-1686.
108. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180: 76-86.
109. Plana M, Garcia F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14: 1921-1933.
110. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1- infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
111. Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol 2000; 43(1 Pt 2): S18-26.
112. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-1445.
113. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-5.
114. Woods ML II, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12: 1491-1494.
115. Mastroianni CM, Trinchieri V, Santopadre P, et al. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. AIDS 1998; 12: 1939-1940.
116. Chou LL, Epstein J, Cassol SA, West DM, He W, Firth JD. Oral mucosal Langerhans' cells as target, effector and vector in HIV infection. J Oral Pathol Med 2000; 29: 394-402.
117. Myint M, Yuan ZN, Schenck K. Reduced numbers of Langerhans cells and increased HLA-DR expression in keratinocytes in the oral gingival epithelium of HIVinfected patients with periodontitis. J Clin Periodontol 2000; 27: 513-9
118. Arany I, Tyring SK. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 1998; 9: 268-271.
119. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296: 292-300.